Grit Andersen
6PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Aug 07, 2024
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.Grit Andersen, Rosy Eloy, Tim Heise
|Sep 22, 2023
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins.Wei Chen, Jia Lu, Leona Plum-Mörschel
|Jan 28, 2023
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.Grit Andersen, Gursharan Singh, Sundara Moorthi Nainar Murugesan
|Jan 12, 2023
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.Grit Andersen, Rosy Eloy, Susanne Famulla
|Dec 18, 2020
ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.Grit Andersen, Grégory Meiffren, Susanne Famulla
|Oct 02, 2020
Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data.Grit Andersen, Leona Plum-Mörschel, Paul D Hockings
Pageof 1
